Icotinib of high dose

DRUG2 trials

Sponsors

Betta Pharmaceuticals Co., Ltd., Tianjin Medical University Cancer Institute and Hospital

Conditions

NSCLCNon-small Cell Lung Cancer

Phase 2

Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease

Betta Pharmaceuticals Co., Ltd.NSCLC

Start: 2012-09-30End: 2016-07-31Target: 180Updated: 2014-12-30

Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR

Tianjin Medical University Cancer Institute and HospitalNon-small Cell Lung Cancer

Start: 2012-10-31End: 2017-12-31Target: 60Updated: 2017-02-07